Inicio 5 News 5 Approved new vaccine for Respiratory Syncytial Virus (RSV)

Approved new vaccine for Respiratory Syncytial Virus (RSV)

25 Nov, 2022

The European Commission has approved ‘Beyfortus’ (nirsevimab) for the prevention of lower respiratory tract infection caused by respiratory syncytial virus (RSV) in newborns and infants during their first RSV season.

RSV is a common and highly contagious seasonal virus that infects almost all children during the first two years of life. It is the most common cause of lower respiratory tract infection in infants, including bronchiolitis and pneumonia.

Beyfortus’, which has been co-developed by Sanofi and AstraZeneca, is the first choice of single-dose RSV protection for a broad infant population, including those born healthy, term or premature, or with specific health conditions.

Despite the overwhelming burden of RSV-associated infections, the pharmaceutical industry had been unable to offer reliable protection against RSV for six straight decades.

Nirsevimab is a recombinant human monoclonal antibody (IgG1) that neutralizes respiratory syncytial virus (RSV).

Nirsevimab, which works on the principle of passive vaccination, is characterized by a long half-life, so a single dose should be sufficient for the entire RSV season, which usually lasts 5 months in autumn-winter.

More information in:


Last News

Últimas noticias

First Gene Therapy for Hemophilia B

Earlier this week, the etranacogene dezaparvovec (Hemgenix) made history as the first gene therapy approved by the US Food and Drug Administration (FDA) for the treatment of the rare genetic disorder hemophilia B. Patients with hemophilia B lack the ability to make a...

6 Supplements People Often Take to Lower “Bad” Cholesterol

Some people believe that dietary supplements such as fish oil, garlic, cinnamon, turmeric, plant sterols, and red yeast rice will lower their "bad" cholesterol. "Bad" cholesterol, known in the medical community as low-density lipoprotein, or LDL, can cause fatty...

10 months of life expectancy makes a difference in ALS

Amylyx Pharmaceuticals Inc's (AMLX.O) drug for amyotrophic lateral sclerosis (ALS) won support from outside advisers to the US Food and Drug Administration on Wednesday, months after the panel rejected it over issues with the test data. ALS, the cause of which is...